• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(CSE:BNXT)

0.3000 UNCHANGED
Streaming Delayed Price Updated: 9:30 AM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BNXT

< Previous 1 2 3 Next >
News headline image
BioNxt Solutions Completes Up-Listing to The OTCQB Market
September 05, 2025
Via ACCESS Newswire
News headline image
Semaglutide API Delivery Enables Start of Lab-Scale ODF Development at BioNxt
September 02, 2025
Via ACCESS Newswire
News headline image
BioNxt Fast-Tracks U.S. Patent for MS Drug and Secures Broad Platform IP Covering Autoimmune Neurology Pipeline
August 20, 2025
Via ACCESS Newswire
News headline image
BioNxt Solutions Reports Pending Patent Grants in Europe and Eurasia, Strengthening IP Protection for Proprietary Sublingual Cladribine-Based MS Treatment
August 05, 2025
Via ACCESS Newswire
News headline image
BioNxt Delivers Positive Results in Patented Cladribine Sublingual Thin-Film Program and Completes Successful Formulation
July 23, 2025
Via ACCESS Newswire
News headline image
BioNxt Solutions Introduces Targeted Chemotherapy Drug Delivery Platform for Precision Oncology
July 08, 2025
Via ACCESS Newswire
News headline image
BioNxt's Sublingual Cladribine Program for MS Ready for Next Phase
July 07, 2025
Via ACCESS Newswire
News headline image
BioNxt Launches Feasibility Study for Semaglutide Oral Thin Film as Alternative to Injection/Tablets
June 23, 2025
Via ACCESS Newswire
News headline image
BioNxt Solutions Provides Bi-weekly MCTO Status Report
May 29, 2025
Via ACCESS Newswire
News headline image
BioNxt Solutions Reports Formal Notice from the European Patent Office of Intention to Grant Patent
May 23, 2025
Via ACCESS Newswire
News headline image
BioNxt Reports Expanded Research, Development and Commercialization Capability with Centralized Munich Laboratory
May 13, 2025
Via ACCESS Newswire
News headline image
BioNxt Solutions Reports Expanded Patent Protection from the Eurasian Patent Organization
May 05, 2025
Via ACCESS Newswire
News headline image
BioNxt Solutions Prepares for Human Bioequivalence Study For MS
April 23, 2025
Via ACCESS Newswire
News headline image
Clarification of Promotional Activities
February 21, 2025
Via ACCESS Newswire
News headline image
BioNxt Solutions Unveils Accelerated 90-Day Plan: Global Patent Advancements, MS Clinical Trial, and Anti-Aging Expansion
February 19, 2025
Via ACCESS Newswire
News headline image
BioNxt Accelerates R&D with Move to Gen-Plus Laboratory in Munich, Germany, Expanding Drug Delivery Research Capabilities
January 21, 2025
Via ACCESS Newswire
News headline image
BioNxt Solutions Expands Patent Protection for Drug Delivery Innovations Backed by Positive IPRP
December 19, 2024
Via ACCESSWIRE
News headline image
BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
December 09, 2024
Via ACCESSWIRE
News headline image
BioNxt Solutions Announces Development of Sublingual Thin-Film for Semaglutide
December 02, 2024
Via ACCESSWIRE
News headline image
BioNxt Announces Enhanced Sublingual Product Development Pipeline with Innovative Solutions for Autoimmune Diseases and Longevity
November 25, 2024
Via ACCESSWIRE
News headline image
Terry Lynch Joins BioNxt as Capital Markets Advisor
October 06, 2024
Via ACCESSWIRE
News headline image
BioNxt Provides Update on Cladribine Program for Multiple Sclerosis, Sublingual Neurodegenerative Disease Patent, and Investor Relations Activities
September 26, 2024
Via ACCESSWIRE
News headline image
BioNxt Receives Positive International Examination Report From the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases
September 09, 2024
Via ACCESSWIRE
News headline image
BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations
August 14, 2024
Via ACCESSWIRE
News headline image
BioNxt Signs Statement of Work with International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development
July 16, 2024
Via ACCESSWIRE
News headline image
BioNxt Signs Master Services Agreement with International Contract Research, Development, and Manufacturing Organization
July 08, 2024
Via ACCESSWIRE
News headline image
BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps
March 17, 2024
Via ACCESSWIRE
BioMedNewsBreaks – BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: BNXTF) (FSE: BXT) Announces Highly Promising Results from ODF Cladribine PK Study
March 14, 2024
Via Investor Brand Network
Topics Intellectual Property
News headline image
BioNxt Reports Successful Results From ODF Cladribine PK Study
March 12, 2024
Via ACCESSWIRE
News headline image
BioNxt Reports Successful Results From ODF Cladribine Toxicity Study
February 07, 2024
Via ACCESSWIRE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap